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OBJECTIVES This study was designed to evaluate the association between vitamin D status and congestive
heart failure (CHF).
BACKGROUND Impaired intracellular calcium metabolism is an important factor in the pathogenesis of CHF.
The etiology of CHF, however, is not well understood.
METHODS Twenty patients age 50 years and 34 patients age 50 years with New York Heart
Association classes 2 and 34 control subjects age 50 years were recruited. N-terminal
pro-atrial natriuretic peptide (NT-proANP), a predictor of CHF severity; vitamin D
metabolites; and parameters of calcium metabolism were measured in fasting blood samples
collected between November 2000 and March 2001.
RESULTS Both groups of CHF patients had markedly increased serum levels of NT-proANP (p 
0.001), increased serum phosphorus levels (p  0.001), and reduced circulating levels of both
25-hydroxyvitamin D (p  0.001) and calcitriol (p  0.001). Albumin-corrected calcium
levels were reduced and parathyroid hormone levels were increased in the younger CHF
patients compared with the controls (both p values 0.001). Moreover, parathyroid hormone
levels tended to be higher in the elderly CHF patients than in the controls (p  0.074). In
a nonlinear regression analysis 25-hydroxyvitamin D and calcitriol were inversely correlated
with NT-proANP (r2  0.16; p  0.001 and r2  0.12; p  0.01, respectively). The vitamin
D genotype at the BmsI restriction site did not differ between the study groups.
CONCLUSIONS The low vitamin D status can explain alterations in mineral metabolism as well as myocardial
dysfunction in the CHF patients, and it may therefore be a contributing factor in the
pathogenesis of CHF. (J Am Coll Cardiol 2003;41:105–12) © 2003 by the American
College of Cardiology Foundation
Congestive heart failure (CHF) is a cardiac dysfunction
syndrome characterized by a reduced left ventricular ejection
fraction (LVEF) in association with water and sodium
retention. Muscle weakness and early fatigue are the two
major symptoms of CHF patients. The prevalence of CHF is
approximately 1% to 3% in Western societies (1,2). Morbidity
and mortality of CHF increase progressively with age (3,4).
The etiology of CHF is not well understood. Obviously,
an altered intracellular handling of ionized calcium (Ca2)
seems to play an important role in the impaired contractility
of the myocardium (5). In isolated myocytes from patients
with terminal heart failure, systolic Ca2 transients were
found to be markedly reduced, diastolic Ca2 levels were
increased, and the rate of diastolic decay of Ca2 was slowed
compared with heart cells from healthy subjects (6). Conse-
quently, digitalis and beta-blockers are frequently used medi-
cations for secondary prevention. They are able to improve
contractility by increasing myocardial intracellular Ca2 levels
(7) and by improving intracellular Ca2 utilization (8).
In a recent observational study in patients with severe
CHF, both vitamin D deficiency and hyperparathyroidism
were common findings (9). Interestingly, vitamin D plays a
pivotal role in cardiac function. Cardiac muscle cells possess
a vitamin D receptor and a calcitriol-dependent Ca2
binding protein (10,11). Moreover, a calcitriol-mediated
rapid activation of voltage-dependent Ca2 channels exists
in cardiac muscle cells (12). Consequently, calcitriol admin-
istration can normalize the impaired contractility of the
myocardium that is observed under experimental vitamin D
deficiency (13,14). Calcitriol also suppresses synthesis and
secretion of the atrial natriuretic peptide (ANP) in cardiac
muscle cells (15). Circulating levels of the N-terminal
pro-ANP (NT-proANP) are massively increased in CHF
patients and are thus a predictor of disease severity (16).
On the basis of these preliminary data, it can be hypoth-
esized that low circulating levels of vitamin D metabolites
are contributing to the pathogenesis and/or the symptom-
atology of CHF. To support this postulate, we performed a
case-control study in younger and older CHF patients.
METHODS
Participants and study design. Fifty-four patients admit-
ted for investigation or treatment of CHF were recruited at
the Heart and Diabetes Center North Rhine-Westfalia
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(geographic latitude: 52°N) between November 2000 and
March 2001. Patients were ambulatory or hospitalized for
not longer than two days. They were classified by New York
Heart Association (NYHA) functional class according to
their cardiac symptoms. Only patients with NYHA classes
2 were included. Moreover, LVEF was determined by
echocardiogram. Cardiac index (CI) and pulmonary wedge
pressure (PCWP) were assessed using right ventricular
cardiac catheterization. Left ventricular ejection fraction
values 35%, CI values 2 l/min/m2, and PCWP values
20 mm Hg are regarded as clinically unfavorable. Patients
were then divided into group I (50 years; n  20) and
group II (50 years; n  34) to evaluate possible age-
related effects. Control group III consisted of 34 elderly
(50 years) free-living subjects. Exercise capacity was as-
sessed by a questionnaire based on NYHA functional
classification (17). Subjects were recruited between Novem-
ber 2000 and March 2001 by an advertisement in several
senior groups in Bonn, Germany (geographic latitude
51°N). Participants of group III were matched for gender,
age, and body mass index with group II (Table 1). All
control subjects had an unlimited exercise capacity (NYHA
class 2). Exclusion criteria were serum creatinine level 2
mg/dl, serum aspartate aminotransferase level 35 U/l, ther-
apy with glucocorticoids or anticonvulsants, and intake of
vitamin D supplements (hospital document/questionnaire).
One blood sample was obtained from the antecubital vein
of each subject after a 12-h overnight fast. Aliquots of whole
blood, plasma, and serum were frozen consecutively at
20°C until analysis. All participants gave written informed
consent to the study, which was approved by the Ethics
Committee of the University of Bonn.
Biochemical analysis. Blood hormone and cytokine anal-
yses are summarized in Table 2. Serum Ca2 and phospho-
rus as well as serum albumin concentrations were assessed
using atomic absorption spectrometry (Ca2) and colori-
metric test kits (phosphorus and albumin; BioMerieux,
Nu¨rtingen, Germany), respectively. Coefficients of variation
were below 2.5%. Total serum Ca2 was corrected with
0.32 mg for each 0.5 mg deviation of concomitant serum
albumin from a normal mean of 4.14 mg (18). Vitamin D
binding protein was measured by single radial immunodif-
fusion (coefficient of variation  10.8%; Immundiagnostik,
Bensheim, Germany). Serum creatinine was determined
enzymatically (test kit: Boehringer, Mannheim, Germany).
Creatinine clearance (ml/min) was estimated according to
the Crockroft-Gault formula (19):
140  age  wt kg
72  serum creatinine mg/dl
Table 1. Characteristics of the Study Groups
CHF Patients
<50 years
(n  20)
CHF Patients
>50 years
(n  34)
Controls
>50 years
(n  34)
Age (yrs) 38.9  7.9 64.1  6.4 68.9  5.2
Male (%) 60.0 61.8 61.8
BMI (kg/m2) 26.3  5.1 25.6  3.8 25.1  2.9
Coronary heart disease (%) 15 44.1 0
Hypertension (%) 0 32.4 41.2
Diabetes (%) 10 23.5 2.9
Drug therapy (%)
Digitalis 60 68 0
Beta-blocker 75 65 5
Vasodilators (including ACE inhibitors) 85 81 11
Diuretics* 85 100 9
Loop diuretics 65 100 0
Thiazide diuretics 40 41 9
Aldosterone antagonists 80 77 0
LVEF (%) 33.9  17.5 29.8  11.1 n.d.
CI (l/min/m2) 2.17  0.51 2.04  0.52 n.d.
PCWP (mm Hg) 22.0  8.4 20.6  8.5 n.d.
Aspartate-aminotransferase (U/l) 10.2  6.5 10.9  4.8 11.9  5.9
Creatinine (mg/dL) 0.98  0.26 1.06  0.36 0.90  0.24
Several patients were taking different kinds of diuretics; n.d.  not determined
ACE  angiotensin-converting enzyme; BMI  body mass index; CHF  congestive heart failure; CI  cardiac index;
LVEF  left ventricular ejection fraction; PCWP  pulmonal capillary wedge pressure.
Abbreviations and Acronyms
Ca2  ionized calcium
CHF  congestive heart failure
CI  cardiac index
LVEF  left ventricular ejection fraction
NT-proANP  N-terminal pro-ANP
NYHA  New York Heart Association
25OHD  25-hydroxyvitamin D
PCWP  pulmonary wedge pressure
PTH  parathyroid hormone
TNF  tumor necrosis factor
UV  ultraviolet
VDR  vitamin D receptor
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Results were reduced by 15% to calculate the creatinine
clearance of female subjects.
The restriction fragment length polymorphism for the
vitamin D receptor (VDR) gene at the BsmI site was
measured with the polymerase chain reaction by using the
method and primers described by Morrison et al. (20). The
presence of a polymorphic restriction site was designated as
b, whereas the absence of this site was designated as B.
Statistics. All statistical evaluations were performed with
the Statistical Package for Social Sciences (SPSS), version
10 (Chicago, Illinois). Normal distribution of the data was
tested by the Kolmogorov-Smirnov test. Normal distribu-
tion was considered if p values were above 0.05. Data were
then evaluated using an analysis of variance (ANOVA)
(normal distributed data) or by the Kruskall-Wallis test
(non-normal data; serum parathyroid hormone, PTH). In
the case of significant differences between subgroups, post
hoc analyses were based on the Tukey test (normal distrib-
uted data) or on the Mann/Whitney U-test. The chi-square
test was used to test differences in the genotype of the
vitamin D receptor between the study groups. Pearson’s
correlation coefficient r (normal distributed data), Spear-
man’s rank correlation coefficient rs (non-normal data), and
nonlinear regression analyses were used to assess interrela-
tionships. A p value 0.05 (two-tailed test) was considered
statistically significant. Data are expressed as mean  SD.
RESULTS
Serum levels of 25-hydroxyvitamin D (25OHD), calcitriol
(Fig. 1), Ca2, Ca2C, phosphorus, and PTH (Table 3)
revealed highly significant differences between the study
groups (ANOVA; all p values 0.001).
Concentration of 25OHD was lower in both patient
groups compared with the elderly control group (Fig. 1).
Moreover, both groups of CHF patients had lower serum
calcitriol levels, lower serum Ca2 levels, and higher phos-
phorus levels than the controls (Fig. 1, Table 3). Reduced
albumin-corrected serum Ca2levels were, however, ob-
served only in the younger CHF patients. Serum PTH
levels were significantly increased in the younger CHF
patients compared with the controls, whereas PTH concen-
trations tended to be higher (p  0.074) only in the elderly
CHF patients compared with the controls. Two of the 34
elderly CHF patients and nine out of the 20 younger CHF
patients, but none of the controls, had hypocalcemia (serum
Ca2  8 mg/dl). Serum vitamin D binding globulin levels
were similar in all groups studied. Patients with CHF and
controls did not differ in the distribution of the genotype for
the VDR gene at the BsmI site (Table 3).
Both age groups of CHF patients had markedly higher
plasma levels of NT-proANP than controls (Fig. 2). Even
in the control subjects, however, the NT-proANP levels of
0.96  0.37 nmol/l were slightly higher than the normal
values published for healthy adults (0.11 to 0.60 nmol/l,
ages 20 to 55 years). Mean serum albumin levels were
significantly lower in the CHF patients compared with the
controls, but they were still in the normal range of 4.0 to 5.4
g/dl (Table 3). Tumor necrosis factor (TNF)-alpha was
significantly increased in the elderly patient group compared
with their age-matched controls (p  0.001). The TNF-
alpha levels of the younger patients did not differ from the
elderly controls. The levels were, however, markedly higher
than the generally accepted mean normal concentrations of
6 pg/ml for healthy middle-aged subjects. Creatinine clear-
ance was highest in the young CHF patients (Table 3).
Calcitriol was correlated with albumin-corrected Ca2
(r  0.48; p  0.001) and was inversely related to PTH
(rs  0.22; p  0.05). Concentration of 25OHD was
correlated with albumin (r  0.24; p  0.05) and vitamin
D binding globulin (r  0.28; p  0.025) and was
inversely related to PTH (rs  0.45; p  0.001), phos-
phorus (r 0.33; p  0.01), and TNF-alpha (r 0.25;
p  0.025). Circulating levels of NT-proANP showed a
nonlinear correlation with 25OHD (Fig. 3), TNF-alpha (r2
 0.27, p  0.001; regression equation: NT-proANP 
1.8TNF-alpha1.258), and calcitriol (r2  0.12, p  0.01;
regression equation: NT-proANP  4.372calcitriol0.769).
Data in Figure 3 indicate that 25OHD levels above 40
ng/ml would be necessary to reduce NT-proANP levels of
almost all subjects close to the normal range of 0.11 to 0.60
nmol/l.
DISCUSSION
This study could demonstrate that reduced circulating levels
of 25OHD and also reduced calcitriol concentrations (Fig.
1) are a typical feature in CHF patients. The associated
increase of serum phosphorus and PTH as well as the
reduced serum Ca2 levels of the CHF patients (Table 3)
Table 2. Blood Hormone and Cytokine Analyses
Parameter Method Interassay CV Normal Range Manufacturer
25-hydroxyvitamin D RIA 11.0% (n  40) 50–200 nmol/l DiaSorin, Stillwater, Minnesota
Calcitriol* Solid-phase extraction/
ELISA
9.0% (n  20) 37–137 pmol/l Immundiagnostik, Bensheim, Germany
Intact parathyroid hormone* ELISA 7.9% (n  8) 10–60 pg/ml DRG Diagnostics, Marburg, Germany
N-terminal propeptide of atrial
natriutrtic peptide†
RIA 8.5% (n  20) 0.11–0.60 mmol/l Biotop Oy, Oulu, Finland
Tumor necrosis factor alpha3 ELISA 7.6% (n  15) 0–20 pg/ml‡ DRG Diagnostics, Marburg, Germany
*Serum samples; †plasma samples; ‡mean values 6 pg/ml.
CV  coefficient of variation; ELISA  enzyme-linked immunosorbent assay; RIA  radioimmunoassay.
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Figure 1. Circulating concentrations (mean  SD) of 25-hydoxyvitamin D (A) and calcitriol (B) in congestive heart failure (CHF) patients and in elderly
healthy controls (50 years). Main effects of study groups were observed (analysis of variance; p  0.001). ***Significant differences between CHF patients
and elderly controls, p  0.001 (post hoc Tukey test); **Significant difference between CHF patients and elderly controls, p  0.025 (post hoc Tukey test).
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can be seen as a consequence of the low vitamin D status
(21). The differences in circulating levels of NT-proANP
(Fig. 2) confirm the classification of patients and controls by
NYHA functional classes (16).
We measured serum Ca2 levels by atomic absorption
spectrometry, which is regarded as the gold standard.
Moreover, our study design allowed samples batching, and
the fasting blood drawing guaranteed that serum Ca2
concentrations were unaffected by dietary Ca2 intake.
Because sufficient amounts of extracellular activator Ca2
are mandatory for the first step in myocardial contraction
(22), adequate influx of activator Ca2 is questionable in the
young CHF patients with low serum levels of albumin-
corrected Ca2 (Table 3). In addition, the low calcitriol
levels of the young and of the elderly CHF patients (Fig. 1)
might also impair calcitriol-dependent intracellular genomic
actions, such as Ca2 binding protein synthesis (10), and
non-genomic actions of Ca2 metabolism, such as
calcitriol-dependent activation of adenylate cyclase (23,24).
Low adenylat cyclase activity can result in an impaired
extracellular Ca2 influx (2,25), decreased Ca2 re-uptake
into the sarcoplasmic reticulum (26), and reduced Ca2
Table 3. Biochemical Parameters and Vitamin D Receptor Genotype of Patients With
Congestive Heart Failure and of Elderly Controls
CHF Patients
<50 years
(n  20)
CHF Patients
>50 years
(n  34)
Controls
>50 years
(n  34)
Albumin (g/dl) 4.61  0.65 4.39  0.58† 5.02  0.30
Intact PTH (pg/ml) 69.3  53.6† 54.6  64.0‡ 31.4  43.1
Ca2 (mg/dl) 7.96  0.76† 8.72  0.72§ 9.16  0.64
Ca2C (mg/dl) 7.72  0.64† 8.56  0.64 8.64  0.72
Phosphorus (mg/dl) 4.38  1.02† 4.14  1.02† 3.49  0.46
DBP (mg/dl) 55.6  12.2 54.8  13.1 59.7  13.5
TNF-alpha (pg/ml) 17.5  11.7 20.6  9.1† 14.0  6.3
Creatinine clearance (ml/min) 118  45† 77  29 83  32
VDR genotype (BB/Bb/bb in %) 35/55/10 26.5/56/17.5 41/41/18
Main effects of study groups were observed for albumin, Ca2, Ca2C, phosphorus, and creatinine clearance (analysis of variance
[analysis of variance]; all p values  0.001), for TNF-alpha (analysis of variance; p  0.025) and for parathyroid hormone
(Kruskall Wallis test; p 0.001). †Significant differences between CHF patients and elderly controls, p 0.001 (post hoc Tukey
test or Mann Whitney U test); ‡borderline significance compared to elderly controls (p 0.074); §significant differences between
CHF patients and elderly controls, p  0.025 (post hoc Tukey test or Mann Whitney U test).
Ca2  calcium; Ca2C  albumin corrected calcium; CHF  congestive heart failure; DBP  vitamin D binding globulin;
PTH  parathyroid hormone; TNF  tumor necrosis factor; VDR  vitamin D receptor.
Figure 2. Blood concentrations (mean  SD) of N-terminal pro-atrial natriuretic peptide (NT-proANP) in congestive heart failure (CHF) patients and
in elderly healthy controls (50 years). Main effects of study groups were observed (analysis of variance; p  0.001). ***Significant differences between CHF
patients and elderly controls, p  0.001 (post hoc Tukey test).
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liberation from the sarcoplasmic reticulum (27). The latter
alteration is considered an important pathogenic factor of
the impaired contractility in cardiomyopathy (6,28).
The pathogenesis of low calcitriol levels in CHF patients
is uncertain. Some earlier studies brought evidence forward
that reduced serum calcitriol levels are the result of low
circulating 25OHD levels (29,30). It has recently been
suggested that TNF-alpha may also suppress calcitriol
synthesis (31). We found an inverse association of TNF-
alpha with 25OHD (results section), indicating that low
25OHD levels are involved in activation of the TNF-alpha
system. Because the creatinine clearance was highest in the
young CHF patients (Table 3), it seems rather unlikely that
an impaired kidney function was responsible for a reduced
renal 1-alpha hydroxylation of 25OHD in the CHF pa-
tients compared with the controls.
25OHD has several independent effects on muscle cells.
Uptake of 45Ca2into cultured cardiac muscle cells is
increased by physiologic concentrations of 25OHD (32).
The 25OHD activity in cardiac muscle cells is on a molar
basis 222 times lower than that of calcitriol (32). However,
at serum concentrations of the two metabolites as those
found in our study groups (Fig. 1), these relative molar
potencies indicate that from 58% to 64% of the circulating
vitamin D activity is contributed by 25OHD. On the basis
of the molar potencies of 25OHD and calcitriol and the
serum concentrations of the two vitamin D metabolites, the
circulating vitamin D activity is 68% in the elderly CHF
patients and only 54% in the younger CHF patients
compared with the control subjects. Moreover, intracellular
Ca2 re-uptake into the sarcoplasmic reticulum is reduced
in experimental vitamin D deficiency (33), which is obvi-
ously not mediated by calcitriol but probably by 25OHD
(27). In addition, intracellular accumulation of phosphate by
muscle might be directly increased by 25OHD (34), an
effect that may be blunted in the case of low circulating
25OHD levels.
We cannot definitively rule out that diuretic therapy of
CHF patients (Table 1) has contributed to the low serum
Ca2 levels. A renal Ca2 leak should, however, result in an
increased serum calcitriol level. Moreover, some case reports
of patients with untreated rickets and with untreated osteo-
malacia suffering from heart failure (35–37) support our
hypothesis that low serum levels of vitamin D metabolites
might be an important cause of the reduced serum Ca2
levels and of the cardiac dysfunction. In these earlier case
reports a rapid normalization of the hypocalcemia and
cardiac symptoms was observed after therapy with Ca2 and
vitamin D (metabolites), and in combination with the
administration of diuretics such as furosemide and spirono-
lactone (35–37). The inverse nonlinear correlation of
25OHD and calcitriol with NT-proANP (Fig. 3 and
Results section) support our hypothesis that the severity of
CHF is increased at low serum levels of vitamin D metab-
olites.
In Europe, circulating levels of 25OHD largely depend
on exposure to ultraviolet (UV) light, namely UV B light
(38). Normally, serum 25OHD decreases with age (36)
because the capability of the skin to produce previtamin D
after UV B irradiation declines with age (39). It is thus an
unexpected finding that even in the younger CHF patients
the vitamin D status is lower than in elderly controls. From
the inclusion criteria of our study we can rule out an
impaired liver function of the CHF patients (Methods
Figure 3. Association between serum N-terminal pro-atrial natriuretic peptide (NT-proANP) and serum 25-hydroxyvitamin D values (r2  0.16; p 
0.001; regression equation: NT-proANP 4.1425OHD0.741).
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section). Possible explanations for the low circulating
25OHD levels may thus be a genetic abnormality of the
hepatic 25-hydroxylase activity, an increased 25OHD ca-
tabolism, or an insufficient UV B exposure and/or inade-
quate dietary vitamin D intake. In this context, it may well
be that a disease-related reduction in outdoor activity
contributes to the low vitamin D status. Granted the pivotal
role of an adequate vitamin D status for the systemic and
myocardial Ca2 metabolism, the CHF patients might
enter into a circulus vitiosus.
There is growing evidence that circulating 25OHD levels
40 ng/ml are necessary to achieve full physiologic vitamin
D actions (40,41). The inverse association between NT-
proANP and 25OHD in our study groups (Fig. 3) supports
this earlier assumption. Not all subjects with relatively low
25OHD levels, however, had high NT-proANP levels (Fig.
3). Thus, additional factors might increase susceptibility to
CHF.
Vitamin D acts through the highly specific vitamin D
receptor. The mechanisms by which the receptor protein
mediates the cellular vitamin D actions are a subject of
intense research. In other vitamin-D-related diseases such
as osteoporosis and diabetes mellitus, the genotype of the
vitamin D receptor at the BmsI restriction site was associ-
ated with disease prevalence (20,42). There is, however, obvi-
ously no relationship between the vitamin D genotype at the
BmsI restriction site and susceptibility to CHF (Table 3).
Our data of alterations in circulating vitamin D metab-
olites and in systemic mineral metabolism in CHF patients
(Fig. 1 and Table 3) and the cellular alterations in
Ca2metabolism found by others (6) are very similar to
those observed in essential hypertension (43). Therapy of
hypertension has successfully been performed by increasing
circulating 25OHD levels through UV B irradiation (44) or
by oral vitamin D supplementation (45). Consequently, a
clear rationale for interventional trials with vitamin D in
combination with a Ca2supplement in chronic CHF
would exist.
In conclusion, this case-control study provides evidence
for an association between a low vitamin D status and CHF
severity. Moreover, data encourage future investigations on
the relationship between vitamin D status and the early
onset of CHF observed in the subgroup of young patients.
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